Adlai Nortye Ltd. (NASDAQ:ANL) Sees Significant Decrease in Short Interest

Adlai Nortye Ltd. (NASDAQ:ANL) was the recipient of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 3,100 shares, a decrease of 27.9% from the October 15th total of 4,300 shares. Based on an average trading volume of 14,400 shares, the short-interest ratio is presently 0.2 days.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Adlai Nortye in a research note on Monday.

Adlai Nortye Price Performance

Shares of ANL stock opened at $3.15 on Thursday. The stock has a 50 day simple moving average of $2.16 and a 200-day simple moving average of $4.53. Adlai Nortye has a 12-month low of $1.85 and a 12-month high of $17.48.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.